About Epsilen Bio
Epsilen Bio develops transformative therapies for patients affected by underserved medical conditions, through stable genomic epigenetic silencing of genes involved in pathological processes.On November 17th, 2021, Epsilen Bio was acquired by Chroma Medicine. Terms of the transaction were not disclosed.
Missing: Epsilen Bio's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Epsilen Bio's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Epsilen Bio
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Epsilen Bio is included in 2 Expert Collections, including Biopharma Tech.
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Companies involved in the capture, sequencing, and/or analysis of genomic, transcriptomic, proteomic, and/or metabolomic data
Latest Epsilen Bio News
Nov 18, 2021
LaingBuisson News Home Healthcare Markets International News Italy: Epsilen Bio acquired by Chroma Medicine, which launches with US$125m in... By Epsilen Bio, a biotechnology company developing transformative therapies through targeted epigenetic silencing of genes, has announced its acquisition by Chroma Medicine, which launches with US$125m in total financing. Atlas Venture and Newpath Partners seeded the US company with participation from Sofinnova Partners. The Series A was led by Cormorant Asset Management with participation by Casdin… You must be a HMI Subscriber to view this content. Login » Nick Herbert has over 30 years’ experience in the financial markets, as both a practitioner and journalist. He started work as an investment banker in London, before joining International Financing Review (IFR) to report on debt capital markets and derivatives. He moved to Singapore in 2000 to manage IFR’s financial markets editorial team throughout Asia, before returning to London in 2009 to take up the position of Publisher for Reuters Capital Markets Publications. For the last five years he has been covering global capital markets, ESG finance and healthcare markets on a freelance basis.
Epsilen Bio Frequently Asked Questions (FAQ)
Where is Epsilen Bio's headquarters?
Epsilen Bio's headquarters is located at Via Vincenzo Gioberti, 8, Milan.
What is Epsilen Bio's latest funding round?
Epsilen Bio's latest funding round is Acquired.
How much did Epsilen Bio raise?
Epsilen Bio raised a total of $2.16M.
Who are the investors of Epsilen Bio?
Investors of Epsilen Bio include Chroma Medicine, Sofinnova Partners and San Raffaele University and Research Hospital.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.